<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27684863</article-id>
      <article-id pub-id-type="pmc">5265956</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000005007</article-id>
      <article-id pub-id-type="art-access-id">05007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5200</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome</article-title>
        <subtitle>A case report and literature review</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Deville</surname>
            <given-names>Clemence</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garrouste</surname>
            <given-names>Cyril</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref>
            <sup>&#x2217;</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coppo</surname>
            <given-names>Paul</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>c</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>d</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Evrard</surname>
            <given-names>Bertrand</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff5">
            <sup>e</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lautrette</surname>
            <given-names>Alexandre</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff6">
            <sup>f</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heng</surname>
            <given-names>Anne Elisabeth</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Guo.</surname>
            <given-names>Weimin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>CHU Clermont-Ferrand, Service de N&#xE9;phrologie, P&#xF4;le REUNNIRH, Clermont-Ferrand</aff>
      <aff id="aff2"><label>b</label>CHU Paris Est, H&#xF4;pital Saint-Antoine, Service d&#x2019;H&#xE9;matologie, AP-HP</aff>
      <aff id="aff3"><label>c</label>Centre de R&#xE9;f&#xE9;rence des Microangiopathies Thrombotiques</aff>
      <aff id="aff4"><label>d</label>Universit&#xE9; Pierre et Marie Curie UPMC Universit&#xE9; Paris 6, Paris</aff>
      <aff id="aff5"><label>e</label>CHU Clermont-Ferrand, Service d&#x2019;Immunologie</aff>
      <aff id="aff6"><label>f</label>CHU Clermont-Ferrand, Service de R&#xE9;animation, P&#xF4;le REUNNIRH, Clermont-Ferrand, France.</aff>
      <author-notes id="cor1">
        <corresp><label>&#x2217;</label>Correspondence: Dr Cyril Garrouste, Department of Nephrology, Clermont-Ferrand University Hospital, CHU Gabriel Montpied, 58 Rue Montalembert, 63003 Clermont-Ferrand, France (e-mail: <email>cgarrouste@chu-clermontferrand.fr</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <volume>95</volume>
      <issue>39</issue>
      <elocation-id>e5007</elocation-id>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>6</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>6</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-95-e5007.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Antifactor H antibody (anti-CFHAb) is found in 6% to 25% cases of atypical hemolytic uremic syndrome (aHUS) in children, but has been only exceptionally reported in adults. There is no consensus about the best treatment for this type of aHUS. We report the case of an adult patient treated successfully with plasma exchange (PE), steroids, and rituximab.</p>
        <p>A 27-year-old Caucasian male presented to hospital with anemia, thrombocytopenia, and acute renal failure. One week earlier, he had digestive problems with diarrhea. The diagnosis of anti-CFHAb-associated aHUS (82,000&#x200A;AU/mL) without <italic>CFHR</italic> gene mutations was established.</p>
        <p>He received Rituximab 375&#x200A;mg/m<sup>2</sup> (4 pulses) with PE and steroids. This treatment achieved renal and hematological remission at day (D) 31 and negative anti-CFHAb at D45 (&lt;100&#x200A;AU/mL). At D76, a fifth rituximab pulse was performed while CD19 was higher than 10/mm<sup>3</sup>. Steroids were stopped at month (M) 9. The patient has not relapsed during long-term follow-up (M39).</p>
        <p>Rituximab therapy can be considered for anti-CFHAb-associated aHUS. Monitoring of anti-CFHAb titer may help to guide maintenance therapeutic strategies including Rituximab infusion.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>adult</kwd>
        <kwd>antifactor H autoantibody</kwd>
        <kwd>case report</kwd>
        <kwd>hemolytic uremic syndrome</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <label>1</label>
      <title>Introduction</title>
      <p>Atypical hemolytic uremic syndrome (aHUS) associated with antifactor H antibodies (anti-CFHAbs) typically occurs in children and teenagers. Anti-CFHAbs have been reported in 6% to 25% of patients in European cohorts<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> and in up to 56% of patients in India.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Only 9 adult cases have been documented.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> Eculizumab is recommended in pediatrics aHUS as treatment of first intention.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> In aHUS associated with anti-CFHAb, immunosuppressive regimens can also be used to achieve clinical remission and anti-CFHAb levels &lt;1000&#x200A;AU/mL.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> However, given its rarity, the management of aHUS with anti-CFHAb remains debated and not consensual, particularly in adults. We report the case of an adult patient with anti-CFHAb-associated aHUS treated successfully with plasma exchange (PE), steroids, and rituximab (RTX).</p>
    </sec>
    <sec>
      <label>2</label>
      <title>Case report</title>
      <p>A 27-year-old male without medical history was admitted to the intensive care unit (ICU) because of acute renal failure, thrombocytopenia, and anemia. One week earlier, he had experienced digestive problems with diarrhea. On ICU admission, he had hyperthermia (38.2&#x200A;&#xB0;C) and jaundice without hepatomegaly.</p>
      <p>Laboratory findings showed microangiopathic hemolytic anemia (hemoglobin 7.3&#x200A;g/dL; reference range 13.0&#x2013;18.0&#x200A;g/dL), hemolysis (haptoglobin&#x200A;&lt;&#x200A;0.08&#x200A;g/dL; reference range 0.6&#x2013;1.6&#x200A;g/dL, lactacte deshydrogenase 2720&#x200A;IU/L; reference range 87&#x2013;241&#x200A;IU/L), and numerous schizocytes on blood smear; thrombocytopenia (21,000 platelets/mm<sup>3</sup>; reference range 150,000&#x2013;450,000 platelets/mm<sup>3</sup>), and acute renal failure (serum creatinine 242&#x200A;&#x3BC;mol/L; reference range 59&#x2013;104&#x200A;&#x3BC;mol/L) with microscopic hematuria (21&#x200A;&#xD7;&#x200A;10<sup>3</sup>/mm<sup>3</sup>) and nephrotic range proteinuria (6.2&#x200A;g/d) consistent with probable glomerular injury. These elements are not suggestive of involvement of dehydration in renal failure. In patients with aHUS, renal biopsies are not recommended<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> owing to the risk of bleeding. We elected not to perform renal biopsy because of severe thrombocytopenia. Bone marrow aspiration was consistent with peripheral thrombocytopenia. Exploration of the complement system showed activation of the alternative pathway with C3 depletion (543&#x200A;mg/L; reference range 660&#x2013;1250&#x200A;mg/L), normal C4 (332&#x200A;mg/mL; reference range 93&#x2013;280&#x200A;mg/mL), low plasma levels of factor B (FB) (72&#x200A;mg/L; reference range 90&#x2013;320&#x200A;mg/mL), and normal antigenic factor H (CFH) (77%; reference range 65%&#x2013;140%). Anti-CFHAbs were positive with a titer of 82,000&#x200A;AU/mL (reference range &lt;100&#x200A;AU/mL). Sequencing analyses evidenced no mutations in <italic>C3</italic>, <italic>FB</italic>, <italic>CFH</italic>, <italic>CFI</italic>, and <italic>MCP</italic> genes.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> A disintegrin-like and metalloprotease with thrombospondin type I repeats-13 (ADAMTS13) was 53%.</p>
      <p>Daily PE with fresh frozen plasma (60&#x200A;mL/kg) was initiated on day (D) 1 of hospitalization and continued until D36. After diagnosis of anti-CFHAb-associated aHUS (D5), immunosuppressive drugs were introduced: steroids (1&#x200A;mg/kg/d) and 4 RTX infusions (375&#x200A;mg/m<sup>2</sup>) at days 5, 7, 13, and 17 of hospitalization (Fig. <xref ref-type="fig" rid="F1">1</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Biological course and treatment of an adult patient with antifactor H antibodies responsible for atypical hemolytic uremic syndrome. Anti-CFHAb = antifactor H antibody. Rituximab (375&#x200A;mg/m<sup>2</sup>) (back arrow).</p>
        </caption>
        <graphic xlink:href="medi-95-e5007-g001"/>
      </fig>
      <p>PE associated with immunosuppression achieved negative anti-CFHAb (&lt;100&#x200A;AU/mL at D45) along with undetectable peripheral B cells, improvement of hematological parameters (at D31 hemoglobin levels had increased to 11.4&#x200A;g/dL and 140,000 platelets/mm<sup>3</sup>), and improvement in renal function (serum creatinine had decreased to 113&#x200A;&#x3BC;mol/L at D31). Anti-CFHAb increased further to 200&#x200A;AU/mL following acute viral gastroenteritis at D56 (Fig. <xref ref-type="fig" rid="F1">1</xref>). At D76, a single RTX infusion (375&#x200A;mg/m<sup>2</sup>) was performed because peripheral B lymphocytes were &gt;10/mm<sup>3</sup>. Steroids were stopped at M9. At M10, there was a rebound of anti-CFHAb followed by spontaneous disappearance a month later, without medical intervention (Fig. <xref ref-type="fig" rid="F1">1</xref>). Laboratory findings showed no hemolysis (haptoglobin 1.04&#x200A;g/dL, 229,000 platelets/mm<sup>3</sup>, hemoglobin 15.3&#x200A;g/dL, no schizocyte on blood smear) and normal serum creatinine at 87&#x200A;&#x3BC;mol/L. At M39, the patient is in complete remission with normal renal function. No complication was observed during follow-up.</p>
    </sec>
    <sec>
      <label>3</label>
      <title>Discussion</title>
      <p>CFH is the main inhibitor of the complement alternative pathway.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> CFH leads to inactivation of the surface-bound C3b cells and inhibits the generation of C3 convertase. Anti-CFHAbs<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> are responsible for acquired functional CFH deficiency and promote complement alternative pathway activation (low C3 and FB plasma levels). Homozygous deletions in complement factor H-related protein 1 (a protein-coding gene) with or without homozygous complement factor H-related protein 3<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> deletion have been observed in 60% to 82.4% of patients with anti-CFHAb-associated aHUS.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup> These patients can have normal plasma C3 levels in more than 1/3 of cases.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup></p>
      <p>Anti-CFHAb-related aHUS has been reported in only 9 adults, 8 males, and 1 female.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup> The characteristics of adults and children with anti-CFH antibody-associated aHUS are different. In children, the mean age is 8.2 years (0.7&#x2013;11.4) with a predominance of female (F/M = 6/4). In the adults, the mean age is 31.5 years (21&#x2013;45) with a predominance of male (F/M = 1/3). The prognosis is more severe in children who have a higher risk of relapse.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> At disease onset, renal disease is often severe with hypertension, oligo-anuria, and dialysis requirement in 30% of cases.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> In a French cohort,<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> extrarenal manifestations were frequently observed<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> such as fever, digestive problems, pancreatitis, hepatitis, seizure, and more rarely cardiac complications.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup></p>
      <p>In France, it has been recommended that all adult patients with aHUS receive daily PE with exchange of 1.5 plasma volume (60&#x200A;mL/kg) as early as possible until the results of ADAMTS 13 and complement investigation.<sup>[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup> Recent pediatric guidelines<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> recommend that eculizumab be started within the first 24 to 48 hours in aHUS or PE if eculizumab is not available immediately. However, results of treatment of anti-CFHAb-related aHUS by eculizumab are scarce (Table <xref ref-type="table" rid="T1">1</xref>). The high cost of eculizumab and the absence of data on the processing time limit its use.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>aHUS outcomes according to treatments.</p>
        </caption>
        <graphic xlink:href="medi-95-e5007-g002"/>
      </table-wrap>
      <p>In a recent retrospective study in 138 children with anti-CFHAb-related aHUS,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> renal survival at M12 in the group treated with PE and induction immunosuppression (steroids and cyclophosphamide or RTX) was better than in the group treated with PE alone, 75.6% and 41.5%, respectively<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> (Table <xref ref-type="table" rid="T1">1</xref>). RTX therapy has been described in case series with good results. In the French cohort, RTX allowed PE weaning in 1 patient and was used in the prevention of (aHUS) relapse after renal transplantation in 3 others became redundant.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> In a retrospective case series<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> of 45 children treated for anti-CFHAb-related aHUS, RTX infusion (n = 14) or cyclophosphamide (n = 31) led to renal remission in 13 (92%) and 29 (93%) cases, respectively. The relapse rates for RTX and cyclophosphamide were 4/13 (31%) and 3/29 (10.5%), respectively. Cyclophosphamide can give good results<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> in patients resistant to induction therapy with PE, steroids, and RTX. Hence, PE and steroids associated with immunosuppressive therapy (cyclophosphamide pulses or rituximab) have been proposed as first-line therapy for induction in patients with anti-CFHAb-related aHUS.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> Plasma exchange removes circulating antibodies. We used RTX rather than cyclophosphamide because RTX leads to specific and rapid (24&#x2013;72 hours) depletion of peripheral B cells, with the exception of plasma cells. In patients with anti-CFHAb-related aHUS treated with RTX, there is a link between peripheral B-cell depletions, decrease in anti-CFHAb rate, and clinical remission.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> Thus, the main mechanism of action of RTX could be the depletion of B cells leading to short-lived plasmocytes that secrete anti-CFHAb (lifespan 10&#x2013;20 days).<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> This would explain why the action of rituximab occurred after 10 to 21 days.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> Cyclophosphamide targets on all cell lines producing antibodies (LcB, LcT, and plamocytes).<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> In addition, RTX is generally well tolerated in autoimmune hematologic diseases. Most frequent side effects include infusional symptoms, serum sickness, and an increased risk of severe infections particularly pyogenic or herpes virus infections, and pneumonitis caused by <italic>Pneumocystis jiroveci</italic>.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Using Cyclophosphamide in young patients may thus induce digestive problems, alopecia, medullar toxicity, and secondary malignancies.</p>
      <p>The pediatric guidelines<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> recommend maintenance treatment with MMF and steroids with an anti-CFHAb target rate &lt;1000&#x200A;AU/mL to avoid relapse. In a retrospective study,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> the relapse-free survival rate was 92.3% with maintenance therapy and 69.1% without treatment at M12.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> New RTX infusions can be used as maintenance therapy when anti-CFHAb are &gt;1000&#x200A;AU/mL, because the rate rises before clinical symptoms.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> For patients who are in complete remission after 1 year and have anti-CFH antibody titers &lt;1000&#x200A;AU/mL and normal C3 rate, it can be envisaged to discontinue treatment.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup></p>
    </sec>
    <sec>
      <label>4</label>
      <title>Conclusion</title>
      <p>In summary, this observation demonstrates the need for rapid detection of anti-CFH antibody in the management of aHUS even when C3 levels are normal and/or there are digestive symptoms in adult patients. Treatment of this form of aHUS with RTX may be beneficial with good outcomes for renal function and platelet levels without long-term relapse. A rituximab preemptive therapy using a monitoring of anti-CFHAb could be considered for anti-CFHAb-associated aHUS.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: aHUS = atypical hemolytic uremic syndrome, Anti-CFHAb = antifactor H antibody, CFH = antigenic factor H, D = day, FB = factor B, ICU = intensive care unit, M = month, PE = plasma exchange, RTX = rituximab.</p>
      </fn>
      <fn fn-type="other">
        <p>Consent: After receiving clear and objective information, the patient gave us his consent for the study.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors have no funding and conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname><given-names>J</given-names></name><name><surname>Janecke</surname><given-names>AR</given-names></name><name><surname>Zimmerhackl</surname><given-names>LB</given-names></name><etal/></person-group>
<article-title>Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome</article-title>. <source><italic>Clin J Am Soc Nephrol</italic></source>
<year>2013</year>; <volume>8</volume>:<fpage>407</fpage>&#x2013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">23243267</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragon-Durey</surname><given-names>MA</given-names></name><name><surname>Loirat</surname><given-names>C</given-names></name><name><surname>Cloarec</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome</article-title>. <source><italic>J Am Soc Nephrol</italic></source>
<year>2005</year>; <volume>16</volume>:<fpage>555</fpage>&#x2013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">15590760</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Gulati</surname><given-names>A</given-names></name><name><surname>Saini</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children</article-title>. <source><italic>Kidney Int</italic></source>
<year>2013</year>; <volume>85</volume>:<fpage>1019</fpage>&#x2013;<lpage>1022</lpage>.<comment>Oct 2</comment>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lionet</surname><given-names>A</given-names></name><name><surname>Prov&#xF4;t</surname><given-names>F</given-names></name><name><surname>Glowacki</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab</article-title>. <source><italic>Nephrol Dial Transplant Plus</italic></source>
<year>2009</year>; <volume>2</volume>:<fpage>458</fpage>&#x2013;<lpage>460</lpage>.</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragon-Durey</surname><given-names>MA</given-names></name><name><surname>Sethi</surname><given-names>SK</given-names></name><name><surname>Bagga</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome</article-title>. <source><italic>J Am Soc Nephrol</italic></source>
<year>2010</year>; <volume>21</volume>:<fpage>2180</fpage>&#x2013;<lpage>2187</lpage>.<pub-id pub-id-type="pmid">21051740</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loirat</surname><given-names>C</given-names></name><name><surname>Fakhouri</surname><given-names>F</given-names></name><name><surname>Ariceta</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>An international consensus approach to the management of atypical hemolytic uremic syndrome in children</article-title>. <source><italic>Pediatr Nephrol</italic></source>
<year>2016</year>; <volume>31</volume>:<fpage>15</fpage>&#x2013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">25859752</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campistol</surname><given-names>JM</given-names></name><name><surname>Arias</surname><given-names>M</given-names></name><name><surname>Ariceta</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document</article-title>. <source><italic>Nefrologia</italic></source>
<year>2013</year>; <volume>33</volume>:<fpage>27</fpage>&#x2013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">23364625</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>A</given-names></name><name><surname>Bacchi</surname><given-names>VF</given-names></name><etal/></person-group>
<article-title>Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome</article-title>. <source><italic>Clin J Am Soc Nephrol</italic></source>
<year>2007</year>; <volume>2</volume>:<fpage>591</fpage>&#x2013;<lpage>596</lpage>.<pub-id pub-id-type="pmid">17699467</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jozsi</surname><given-names>M</given-names></name><name><surname>Strobel</surname><given-names>S</given-names></name><name><surname>Dahse</surname><given-names>HM</given-names></name><etal/></person-group>
<article-title>Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome</article-title>. <source><italic>Blood</italic></source>
<year>2007</year>; <volume>110</volume>:<fpage>1516</fpage>&#x2013;<lpage>1518</lpage>.<pub-id pub-id-type="pmid">17495132</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skerka</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Bacchi</surname><given-names>VF</given-names></name><etal/></person-group>
<article-title>Complement factor H related proteins (CFHRs)</article-title>. <source><italic>Mol Immunol</italic></source>
<year>2013</year>; <volume>56</volume>:<fpage>170</fpage>&#x2013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">23830046</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorcy</surname><given-names>N</given-names></name><name><surname>Rioux-Leclercq</surname><given-names>N</given-names></name><name><surname>Lombard</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Three kidneys, two diseases, one antibody?</article-title>
<source><italic>Nephrol Dial Transplant</italic></source>
<year>2011</year>; <volume>26</volume>:<fpage>3811</fpage>&#x2013;<lpage>3813</lpage>.<pub-id pub-id-type="pmid">21813829</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><name><surname>Fakhouri</surname><given-names>F</given-names></name><name><surname>Garnier</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults</article-title>. <source><italic>Clin J Am Soc Nephrol</italic></source>
<year>2013</year>; <volume>8</volume>:<fpage>554</fpage>&#x2013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">23307876</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loirat</surname><given-names>C</given-names></name><name><surname>Fr&#xE9;meaux-Bacchi</surname><given-names>V</given-names></name></person-group>
<article-title>Atypical hemolytic uremic syndrome</article-title>. <source><italic>Orphanet J rare Dis</italic></source>
<year>2011</year>; <volume>6</volume>:<fpage>60</fpage>.<pub-id pub-id-type="pmid">21902819</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>M</given-names></name><name><surname>Goodship</surname><given-names>T</given-names></name></person-group>
<article-title>How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome</article-title>. <source><italic>Br J Haematol</italic></source>
<year>2014</year>; <volume>164</volume>:<fpage>759</fpage>&#x2013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">24387053</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Nester</surname><given-names>CM</given-names></name></person-group>
<article-title>Syndromes of thrombotic microangiopathy</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2014</year>; <volume>371</volume>:<fpage>654</fpage>&#x2013;<lpage>666</lpage>.<pub-id pub-id-type="pmid">25119611</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandelwal</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolutic uremic syndrome</article-title>. <source><italic>Pediatr Nephrol</italic></source>
<year>2015</year>; <volume>30</volume>:<fpage>451</fpage>&#x2013;<lpage>457</lpage>.<pub-id pub-id-type="pmid">25217328</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sana</surname><given-names>G</given-names></name><name><surname>Dragon-Durey</surname><given-names>MA</given-names></name><name><surname>Charbit</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses</article-title>. <source><italic>Pediatr Nephrol</italic></source>
<year>2014</year>; <volume>29</volume>:<fpage>75</fpage>&#x2013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23868108</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loirat</surname><given-names>C</given-names></name><name><surname>Fr&#xE9;meaux-Bacchi</surname><given-names>V</given-names></name></person-group>
<article-title>Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better</article-title>. <source><italic>Kidney Int</italic></source>
<year>2014</year>; <volume>85</volume>:<fpage>1019</fpage>&#x2013;<lpage>1022</lpage>.<pub-id pub-id-type="pmid">24786877</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Quintrec</surname><given-names>M</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Noel</surname><given-names>LH</given-names></name><etal/></person-group>
<article-title>Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome</article-title>. <source><italic>Am J Transplant</italic></source>
<year>2009</year>; <volume>9</volume>:<fpage>1223</fpage>&#x2013;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">19422347</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froissart</surname><given-names>A</given-names></name><name><surname>Veyradier</surname><given-names>A</given-names></name><name><surname>Hi&#xE9;</surname><given-names>M</given-names></name><etal/></person-group>
<collab>French Reference Center for Thrombotic Microangiopathies</collab>. <article-title>Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story</article-title>. <source><italic>Eur J Intern Med</italic></source>
<year>2015</year>; <volume>26</volume>:<fpage>659</fpage>&#x2013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">26293834</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartron</surname><given-names>G</given-names></name><name><surname>Watier</surname><given-names>H</given-names></name><name><surname>Golay</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>From the bench to the bedside: ways to improve rituximab efficacy</article-title>. <source><italic>Blood</italic></source>
<year>2004</year>; <volume>104</volume>:<fpage>2642</fpage>.</mixed-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Bagga</surname><given-names>A</given-names></name></person-group>
<article-title>Rituximab therapy in nephrotic syndrome: implications for patients management</article-title>. <source><italic>Nat Rev Nephrol</italic></source>
<year>2013</year>; <volume>9</volume>:<fpage>154</fpage>&#x2013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">23338210</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Hataya</surname><given-names>H</given-names></name><name><surname>Saida</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan</article-title>. <source><italic>Clin Exp Nephrol</italic></source>
<year>2015</year>; <volume>20</volume>:<fpage>265</fpage>&#x2013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">26156042</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakhouri</surname><given-names>F</given-names></name><name><surname>Delmas</surname><given-names>Y</given-names></name><name><surname>Provot</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases</article-title>. <source><italic>Am J Kidney Dis</italic></source>
<year>2014</year>; <volume>63</volume>:<fpage>40</fpage>&#x2013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">24021908</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
